Patel et al. showed that administration of Aib2 C24, another dual GLP-1/GCG receptor agonist, alongside HFD feeding, prevented the development of hepatic steatosis, inflammation, and fibrosis in mice [44]. This evidence concerns the gene GCG and fatty liver disease.